HC010
Phase 2Small molecule
HC010 is one of 143 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
142
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
286 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Tagrisso
AstraZenecaPhase 2
Mektovi
PfizerPhase 2
Myrbetriq
AstellasPhase 2
Tarceva
OOSI Pharmaceuticals
Phase 2
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HC010. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHC Biopharma Inc.